By proceeding, you agree to our Terms of Use and Privacy Policy.
Using case histories, we will highlight pitfalls that are common to the early stages of drug development programs to help you avoid unnecessary delays and costly rework. The early stages of drug development rely on an effective interplay between several different disciplines.
Attend a webinar that provides lessons from real case histories.
Learn cutting-edge information about the challenges of early drug development.
Find important considerations for embarking on a new drug development program, illustrated with several examples.
Connect with Dr. Norbert Makori, Vice President at Altasciences; Dr. Hazel Clay, Drug Development Advisor, Altasciences and get inspired.
25-28 September 2023
Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.
Event Started
Hybrid
Paid
Boston
26-27 September 2023
The coronavirus pandemic ignited interest in learning more about immune responses to infections, their downstream effects, and how they can be modulated. It also gave rise to increased awareness of the role of immunity in diseases like cancer, neurod
Cambridge Healthtech Institute’s two-part conference on Artificial Intelligence (AI)/Machine Learning (ML)-Enabled Drug Discovery will highlight the increasing use of computational tools, AI modeling, algorithms, and data science for identifying nove
While finding novel druggable targets and drug modalities for therapeutic intervention remains a top priority for the pharma/biotech industry, identifying and validating "good" targets and leads remains challenging. Cambridge Healthtech Institute’s c
Cambridge Healthtech Institute's GPCR-Based Drug Discovery conference is now in its 18th year. G protein-coupled receptors (GPCRs), because of their central role in so many cellular processes, are still among the largest class of molecules modulated
Small molecule-based therapeutic options against traditionally hard-to-drug intracellular oncology targets (like KRAS) are being discovered at a more rapid pace and a few have even reached the market in the past few years. Not only do small molecules
As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an altern
A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are
Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets conference focuses on therapeutic candidates in clinical or earlier stage development that modulate molecules or cellular processes involved in neurodegenerative diseases, especial
The first pass category is available exclusively to Pharma, Biopharmaceutical and Medical Device companies. Eligibility is subject to approval by the Arena International team.The second pass category is available to vendors, service provi
USA
San Diego
Outsourcing made easy with a one-stop solution to early phase drug development.
It was a great event to attend. Highly recommended.
It was a very impressive event. I really enjoyed it.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.